Plasma concentrations of glucose were determined using commercial colorimetric assays (#G7521; Pointe Scientific Inc., Canton, MI). Plasma concentrations of IGF-1 were measured using a commercial ELISA kit validated for bovine samples (SG100; R&D Systems Inc., Minneapolis, MN; Moriel et al., 2012 (link)). Commercial bovine-specific ELISA kits were utilized to determine the plasma concentrations of IGF-2 (LS-F51244; LifeSpan BioSciences, Inc., Seattle, WA) and serum concentrations of IgG (E11-118; Bethyl Laboratories, Inc., Montgomery, TX). Plasma concentrations of NEFA were determined using a commercial kit (HR Series NEFA-2; Wako Pure Chemical Industries Ltd, Richmond, VA; Pescara et al., 2010 (link)). Intra-assay and interassay CV for assays of glucose, IGF-1, IGF-2, IgG, and NEFA were 1.44 and 2.23, 3.68 and 4.11, 4.98 and 5.77, 3.21% and 4.45%, and 2.23% and 1.49%, respectively.
E11 118
Manufactured by Fortis Life Sciences
Sourced in United States
The E11-118 is a laboratory equipment designed for general use. It serves as a tool for conducting various scientific experiments and analyses. The core function of this product is to provide a controlled and reliable environment for various laboratory procedures.
Automatically generated - may contain errors
Lab products found in correlation
G7521, by Horiba (2 mentions)
Sg100, by R&D Systems (2 mentions)
Ls f51244, by LifeSpan BioSciences (2 mentions)
Hr series nefa 2, by Fujifilm (2 mentions)
Advia 1800, by Siemens (2 mentions)
E11 101, by Fortis Life Sciences (2 mentions)
E11 131, by Fortis Life Sciences (2 mentions)
Q 0122, by Agilent Technologies (2 mentions)
4 protocols using e11 118
1
Plasma Biomarker Quantification Protocol
2
Quantifying Plasma Immunoglobulins and Acute-Phase Proteins
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Plasma concentrations of IgG, IgM, and IgA were determined by ELISA (E11-118, E11-101, and E11-131 respectively; Bethyl Laboratories Inc., Montgomery, TX) according to the manufacturer's guidelines. All intra-assay coefficients of variation (CV) were ≤5%, and inter-assay CV were ≤ 6%.
Plasma total protein concentrations were determined using an ADVIA 1800 analyzer (Siemens Medical Solutions, Erlangen, Germany). Albumin concentrations in plasma were measured by bromocresol green-binding and spectrophotometric determination at 596 nm (ADVIA 1800; Siemens Medical Solutions). Fibrinogen concentrations in plasma were measured by a particlebound polyclonal rabbit anti-fibrinogen antibody (Q 0122; DakoCytomation, Glostrup, Denmark), followed by a turbidimetric assay (ADVIA 1800; Siemens Medical Solutions). A spectrophotometric assay was used to analyze plasma haptoglobin concentrations, following the manufacturer's guidelines (TP-801; Tridelta Developments Ltd., Kildare, Ireland). For the abovementioned analyses, all intra-assay CV were ≤3% and inter-assay CV were ≤4%. Serum amyloid A (SAA) concentrations in plasma were determined by ELISA (TP-802; Tridelta Developments Ltd.) according to the manufacturer's guidelines. All intra-assay CV for SAA were ≤ 5%, and inter-assay CV were ≤ 6%.
Plasma total protein concentrations were determined using an ADVIA 1800 analyzer (Siemens Medical Solutions, Erlangen, Germany). Albumin concentrations in plasma were measured by bromocresol green-binding and spectrophotometric determination at 596 nm (ADVIA 1800; Siemens Medical Solutions). Fibrinogen concentrations in plasma were measured by a particlebound polyclonal rabbit anti-fibrinogen antibody (Q 0122; DakoCytomation, Glostrup, Denmark), followed by a turbidimetric assay (ADVIA 1800; Siemens Medical Solutions). A spectrophotometric assay was used to analyze plasma haptoglobin concentrations, following the manufacturer's guidelines (TP-801; Tridelta Developments Ltd., Kildare, Ireland). For the abovementioned analyses, all intra-assay CV were ≤3% and inter-assay CV were ≤4%. Serum amyloid A (SAA) concentrations in plasma were determined by ELISA (TP-802; Tridelta Developments Ltd.) according to the manufacturer's guidelines. All intra-assay CV for SAA were ≤ 5%, and inter-assay CV were ≤ 6%.
3
Bovine Plasma and Serum Assays
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Commercial ELISA kits validated for bovine samples were utilized to determine the cow plasma concentrations of IGF-1 (SG100; R&D Systems, Inc., Minneapolis, MN; Moriel et al., 2012 (link)) and IGF-2 (LS-F51244; LifeSpan BioSciences, Inc., Seattle, WA; Palmer et al., 2020 (link)) and calf serum concentrations of IgG (E11-118; Bethyl Laboratories, Inc., Montgomery, TX).-Commercial bovine quantitative colorimetric kits were utilized to assess the plasma concentrations of glucose (#G7521; Pointe Scientific, Inc., Canton, MI) and NEFA (HR Series NEFA-2; Wako Pure Chemical Industries, Ltd. USA, Richmond, VA; Pescara et al., 2010 (link)). Intra-assay and inter-assay CV for assays for concentrations of glucose, IGF-1, IGF-2, NEFA, and IgG were 2.23 and 2.86, 2.96 and 3.12, 4.77 and 4.99, 3.46 and 4.11 and 3.23 and 2.55%, respectively.
4
Plasma Protein Concentration Measurements
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Plasma albumin concentrations were measured by using bromocresol green-binding and spectrophotometrical determination at 596 nm (ADVIA 1800; Siemens Medical Solutions, Tarrytown, NY). Plasma total protein concentrations were measured by using an ADVIA 1800 analyzer (Siemens Medical Solutions, Erlangen, Germany). Plasma Hp concentrations were measured by using a spectrophotometric assay according to the manufacturer's guidelines (TP-801; Tridelta Developments Ltd., Kildare, Ireland). Fibrinogen concentrations in plasma were measured by using a particle-bound polyclonal rabbit anti-fibrinogen antibody (Q 0122; DakoCytomation, Glostrup, Denmark), followed by a turbidimetric assay (ADVIA 1800; Siemens Medical Solutions). All intra-assay CV were ≤3%, and inter-assay CV were ≤4%.
Plasma SAA concentrations were determined by ELISA (TP-802; Tridelta Developments Ltd.) according to the manufacturer's guidelines. Plasma IgG, IgM, and IgA concentrations were determined by ELISA (E11-118, E11-101, and E11-131 respectively; Bethyl Laboratories Inc., Montgomery, TX) according to the manufacturer's guidelines. All intra-assay CV were ≤5%, and inter-assay CV were ≤6%.
Plasma SAA concentrations were determined by ELISA (TP-802; Tridelta Developments Ltd.) according to the manufacturer's guidelines. Plasma IgG, IgM, and IgA concentrations were determined by ELISA (E11-118, E11-101, and E11-131 respectively; Bethyl Laboratories Inc., Montgomery, TX) according to the manufacturer's guidelines. All intra-assay CV were ≤5%, and inter-assay CV were ≤6%.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!